arrow_rightarrow_righticon_excelicon_pficon_ppticon_wordmagnifier

Scientific Programme

Thursday 09 Nov

12:30

Welcome

Session: From basic science to clinical application

Chair: Jan B. Vermorken (BE)

13:00

Oral potentially malignant disorders (OPMD): an update

Ruud Brakenhoff (NL)

13:25

The role of artificial intelligence in OPMD

Pierre Saintigny (F)

13:50

Treatment of OPMD and first results of immune checkpoint inhibitors

Paolo Bossi (I)

14:15

Innovations in cell-based assays for drug discovery and drug evaluation

Ingeborg Tinhofer (DE)

14:40

Break and poster viewing

15:10

Is the ESCAT ranking of support in head and neck cancer management?

Maud Kamal (F)

15:35

Mechanism of action and potential use of SMAC mimetics in HNSCC

Ben O’Leary (UK)

16:00

Precision medicine beyond genomics

Enrique Sanz (CA)

16:25

Proffered paper session 1

chaired by René Leemans (NL)

O01: Preclinical study on the potential of PI3K/Akt pathway inhibition in overcoming cetuximab resistance and inducing immunogenic cell death using 2D and 3D models
Hannah Zaryouh (BE)

O02: Prognostic and predictive value of tumor infiltrating cells on oncological outcomes in advanced laryngeal cancer
Marta Mękarska (PO)

O03: Prognostic and predictive role of pre- and post- treatment GPS variation in early or locally advanced head and neck cancer patients
Simona Bui (IT)

O04: The modified Polsby-Popper score is a novel quantitative histomorphology biomarker with potential to predict lymph node positivity and cancer-specific survival in tongue squamous cell carcinoma
Tamás Dániel Csűry (GE)

O05: Re-irradiation and PD-1 blockade in recurrent squamous cell head and neck carcinomas, results from the phase I REPORT-trial
Hanne Astrid Eide (NO)

17:30

Clinical cases: Panel discussion

chaired by Brian O’Sullivan (CA)

Panel: René Leemans, Piero Nicolai, Maria Isabel Falguera Uceda, Hans Langendijk, Jorge Contreras, Jean-Pascal Machiels, Antonio Rueda, Marc Oliva, Almudena Pérez Lara, Paolo Bossi, Carlos Chiesa Estomba

19:00

News from the European Head & Neck Society (EHNS)

Giovanni Succo (I)

19:15

Welcome reception

Friday 10 Nov

Symposium of the Flemish Working Group Head and Neck Cancers (VWHHT)

Moderator: Willem Lybaert (BE)

07:30

Organoids in HNSCC: development and outlooks

Gilles Van Haesendonck, Hanne Verswyvel and Hannah Zaryouh (BE)

Speakers:
Gilles Van Haesendonck, Department ENT & Head- and neck surgery, Antwerp University Hospital, Belgium
Hanne Verswyvel, Center for Oncological Research & PLASMANT, UAntwerp, Belgium
Hannah Zaryouh Center for Oncological Research, UAntwerp, Belgium

08:00

Prophylactic swallowing exercises in HNSCC patients during radiotherapy – PRESTO-trial: differences in adherence and outcome variables

Margot Baudelet (BE)

Speaker:
Margot Baudelet, SLP, Department of Otorhinolaryngology and Radiation Oncology, University Hospital Ghent, Belgium

Session Primary disease (1)

Chair Hans Langendijk (NL)

08:30

Sentinel Node Biopsy in cN0 Early-Stage Oral Cavity Cancer: what is the evidence?

Clare Schilling (UK)

08:55

Partial laryngeal surgery in 2023

Giovanni Succo (I)

09:20

Managing the internal carotid artery in head and neck cancer: where are we?

Piero Nicolai (I)

09:45

Improving quality of reconstructive surgery in head and neck cancer

Sat Parmar (UK)

10:10

Coffee break and poster viewing

10:45

Innovation in radiotherapy: “FLASH-therapy”

Jean Bourhis (CH)

11:10

Hypoxia in head and neck cancer: current relevance

Olivier Feron (BE)

11:35

Hyperthermia: a game changer in the management of head and neck cancer?

Anthony Kong (UK)

12:00

Clinical cases: Panel discussion

chaired by Piero Nicolai (I)

Panel: René Leemans, Carlos Chiesa Estomba, Maria Isabel Falguera Uceda, Jean-Pascal Machiels, Antonio Rueda, Marc Oliva, Kevin Harrington, Jorge Contreras, Almudena Pérez Lara, Petr Szturz

13:30

Lunch and poster viewing

Session Primary disease (2)

Chair: Piero Nicolai (I)

14:30

Prognostic factors in HPV-positive oropharyngeal cancer: an update

Brian O’Sullivan (CA)

14:55

Immunotherapy and novel agents in locoregionally advanced HNSCC

Jean-Pascal Machiels (BE)

15:20

Is reducing the extent of local treatments justified after successful neoadjuvant therapy?

Andreas Dietz (DE)

15:45

Noninvasive biomarkers predicting outcome in patients with locoregionally advanced HNSCC

Ricard Mesia (ES)

16:10

Coffee break

16:40

Innovations in head and neck surgery in the 21st century

René Leemans (NL)

17:05

Impact of emerging technology developments in proton therapy

Hans Langendijk (NL)

17:30

Proffered paper session 2

chaired by Jean-Pascal Machiels (BE)

O06: The extent of unnecessary tooth loss due to extractions prior to radiotherapy based on radiation field and dose in patients with head and neck cancer
Doke Buurman (NL)

O07: Patient-reported factors contributing to decreased oral intake during radiotherapy in head and neck cancer
Alice Vergauwen (BE)

O08: Repair of Tracheoesophageal Puncture with Bovine Pericardium: A Pilot Case Series
Misha Chew (UK)

O09: Texture analysis for detection of head and neck squamous cell carcinoma recurrences
Almudena Pérez-Lara (ES)

O10: Patterns of Care in de novo Oligo-metastatic and Oligo-recurrent Head and Neck Cancers: A Head and Neck Cancer International Group Survey
Monali Swain (IN)

18:30

News from EORTC-HNCG

Jean Pascal Machiels (BE)

18:45

Debate

moderator Jan Vermorken (BE)

This house believes that hypoxic modification should be used to enhance the effect of
(chemo)radiation in patients with locoregionally advanced HNSCC
Pro-position: Jens Overgaard (seconded by Jean Bourhis (CH))
Contra-position: Vincent Gregoire (seconded by Hans Langendijk (NL))

Saturday 11 Nov

08:15

News from the Head and Neck Cancer International Group (HNCIG)

Petr Szturz (CH)

Session Recurrent/Metastatic (R/M) disease

Chair: Brian O’Sullivan (CA)

08:30

50 years of systemic therapy: what have we gained?

Jan Vermorken (BE)

08:55

The potential roles of Antibody-Drug Conjugates in head and neck cancer

Christophe Le Tourneau (F)

09:20

Intratumoral drug administration: more potential in head and neck cancer?

Kevin Harrington (UK)

09:45

Sponsored lecture

More information: https://www.thno2023.org/sponsors/

10:10

Coffee break

10:45

Metronomic chemotherapy and immunotherapy: a fascinating approach

Kumar Prabhash (IN)

11:10

Metastatic head and neck cancer: what is the optimal local treatment?

Petr Szturz (CH)

Session Salivary Gland cancer

11:35

Molecular characterization of salivary gland cancer and treatment implications

Alberto Hernando (ES)

12:00

Salivary duct carcinoma: strategies to improve outcome

Lisa Licitra (I)

12:25

General discussion

13:00

Adjourn